RNXT RenovoRx, Inc.
RenovoRx, Inc. (RNXT) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +25.0% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About RenovoRx, Inc.
RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.
Sector
Healthcare
Industry
Drug Delivery